Overview
2009Founded1
Compare with Aditxt, Inc., One World Products, Inc. or Processa Pharmaceuticals, Inc., or pick any stock.
- TickerATOS on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersSeattle1
- Websiteatossatherapeutics.com
- Incorporated inDE4
- Business address1448 Nw Market Street, Suite 500, Seattle, Wa 981074
- Filer categoryNon-accelerated filer, Smaller reporting company4
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $21.2M | $14.1M |
| General and administrative | $16.0M | $13.5M |
| Total operating expenses | $37.1M | $27.6M |
| Operating loss | -$37.1M | -$27.6M |
| Impairment charge on investment in equity securities | $0 | -$1.7M |
| Interest income | $2.4M | $4.0M |
| Other expense, net | -$6.0K | -$223.0K |
| Loss before income taxes | -$34.8M | -$25.5M |
| Income taxes benefit | $0 | $0 |
| Net loss | -$34.8M | -$25.5M |
| Net loss per share of common stock - basic (in dollars per share) | -$4.04 | -$3.04 |
| Net loss per share of common stock - diluted (in dollars per share) | -$4.04 | -$3.04 |
| Weighted average shares outstanding used to compute net loss per share- basic (in shares) | 8.6M shares | 8.4M shares |
| Weighted average shares outstanding used to compute net loss per share - diluted (in shares) | 8.6M shares | 8.4M shares |
Every line of the balance sheet in the latest annual report, as filed.10
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $41.3M | $71.1M | |
| Restricted cash | $110.0K | $110.0K | |
| Prepaid materials | $3.1M | $2.1M | |
| Prepaid expenses and other current assets | $1.1M | $1.2M | |
| Total current assets | $45.6M | $74.5M | |
| Other assets | $2.0M | $2.0M | |
| Total Assets | $47.6M | $76.4M | |
| Accounts payable | $4.3M | $679.0K | |
| Accrued expenses | $1.3M | $919.0K | |
| Payroll liabilities | $1.6M | $1.9M | |
| Other current liabilities | $1.1M | $1.5M | |
| Total current liabilities | $8.3M | $5.0M | |
| Total Liabilities | $8.3M | $5.0M | |
| Common stock - $0.18 par value; 350,000,000 shares authorized 8,611,361 and 8,611,266 shares issued and outstanding as of December 31, 2025 and 2024 | $1.6M | $1.6M | |
| Additional paid-in capital | $285.8M | $283.2M | |
| Treasury stock, at cost; 88,003 shares of common stock at December 31, 2025 and 2024 respectively | -$1.5M | -$1.5M | |
| Accumulated deficit | -$246.6M | -$211.8M | |
| Total Stockholders' Equity | $39.4M | $71.5M | |
| Total Liabilities and Stockholders' Equity | $47.6M | $76.4M | |
| Preferred stock, par value (in dollars per share) | $0.00 | ||
| Preferred stock, authorized (in shares) | 10.0M shares | ||
| Common stock, par value (in dollars per share) | $0.18 | $0.18 | $0.18 |
| Common stock, authorized (in shares) | 350.0M shares | 350.0M shares | 350.0M shares |
| Common stock, issued (in shares) | 8.6M shares | 8.6M shares | |
| Common stock, outstanding (in shares) | 8.6M shares | 8.6M shares | |
| Treasury stock, shares (in shares) | 88.0K shares | 88.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.10
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$34.8M | -$25.5M |
| Stock-based compensation | $2.6M | $2.3M |
| Impairment charge on investment in equity securities | $0 | $1.7M |
| Depreciation | $16.0K | $17.0K |
| Loss on disposal of assets | $0 | $7.0K |
| Prepaid materials | -$983.0K | -$611.0K |
| Prepaid expenses and other current assets | $37.0K | $997.0K |
| Other assets | $4.0K | $331.0K |
| Accounts payable | $3.6M | -$127.0K |
| Accrued expenses | $388.0K | -$54.0K |
| Payroll liabilities | -$304.0K | $208.0K |
| Other current liabilities | -$410.0K | -$296.0K |
| Net cash used in operating activities | -$29.8M | -$21.0M |
| Purchase of property and equipment | -$23.0K | -$19.0K |
| Net cash used in investing activities | -$23.0K | -$19.0K |
| Proceeds from exercise of warrants | $0 | $3.7M |
| Net cash provided by financing activities | $0 | $3.7M |
| NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | -$29.8M | -$17.4M |
| Common stock issued upon cashless exercise of stock options | $0 | $273.0K |
| Conversion of Series B convertible preferred stock to common stock | $5.0K | $0 |
Compare Atossa Therapeutics (United States) with another company
Former names
- ATOSSA GENETICS INCMar 30, 2010 to Nov 13, 20194
Timeline
- 2009Founded Founded1
Recent filings
- Oct 9, 20268-K
- Sep 29, 20268-K
- Sep 18, 20268-K
- Aug 7, 202610-Q
- Aug 7, 20268-K
- Jun 12, 2026424B5
- Jun 11, 20268-K
- May 14, 20264
- May 14, 20264
- May 14, 20264
- May 14, 20264
- May 14, 20264
- May 14, 20264
- May 8, 20268-K
- May 8, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- WikidataQ107517747
- SEC EDGARCIK 1488039
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Company websiteAtossa Therapeutics (United States) logo
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12